PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Potential Cardiovascular and Renal Protective Effects of Vitamin D and Coenzyme Q10 in l-NAME-Induced Hypertensive Rats.

Abstract Hypertension is one of the primary modifiable risk factors for cardiovascular disease. Adequate vitamin D (vit D) levels have been shown to reduce vascular smooth muscle contraction and to increase arterial compliance, which may be beneficial in hypertension. Further, coenzyme Q10 (COQ10) through its action to lower oxidative stress has been reported to have beneficial effects on hypertension and heart failure. This study examined the possible cardiac and renal protective effects of vit D and COQ10 both separately and in combination with an angiotensin II receptor blocker, valsartan (vals) in l-NAME hypertensive rats.
PMID
Related Publications

Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.

Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.

Effects of losartan on blood pressure, oxidative stress, and nitrate/nitrite levels in the nitric oxide deficient hypertensive rats.

Barnidipine ameliorates the vascular and renal injury in L-NAME-induced hypertensive rats.

Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury.

Authors

Mayor MeshTerms
Keywords

Antioxidants

Coenzyme Q10

Vitamin D

l-Arginine analog hypertensive rats

Journal Title the american journal of the medical sciences
Publication Year Start




PMID- 28864378
OWN - NLM
STAT- MEDLINE
DA  - 20170902
DCOM- 20170908
LR  - 20170908
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 354
IP  - 2
DP  - 2017 Aug
TI  - Potential Cardiovascular and Renal Protective Effects of Vitamin D and Coenzyme
      Q10 in l-NAME-Induced Hypertensive Rats.
PG  - 190-198
LID - S0002-9629(17)30213-6 [pii]
LID - 10.1016/j.amjms.2017.04.007 [doi]
AB  - BACKGROUND: Hypertension is one of the primary modifiable risk factors for
      cardiovascular disease. Adequate vitamin D (vit D) levels have been shown to
      reduce vascular smooth muscle contraction and to increase arterial compliance,
      which may be beneficial in hypertension. Further, coenzyme Q10 (COQ10) through
      its action to lower oxidative stress has been reported to have beneficial effects
      on hypertension and heart failure. This study examined the possible cardiac and
      renal protective effects of vit D and COQ10 both separately and in combination
      with an angiotensin II receptor blocker, valsartan (vals) in l-NAME hypertensive 
      rats. MATERIALS AND METHODS: Hypertension was induced in rats by l-NAME
      administration. Following induction of hypertension, the rats were assigned into 
      the following 6 subgroups: an l-NAME alone group and treated groups receiving the
      following drugs intraperitoneally for 6 weeks; vals, vit D, COQ10 and combination
      of vals with either vit D or COQ10. A group of normotensive rats were used as
      negative controls. At the end of the treatment period, blood pressure, serum
      creatinine, blood urea nitrogen, lipids and serum, cardiac and renal parameters
      of oxidative stress were measured. RESULTS: Compared to the l-NAME only group,
      all treatments lowered systolic, diastolic, mean arterial pressure, total
      cholesterol, low-density lipoprotein cholesterol, and creatinine levels as well
      as TNF-alpha and malondialdehyde. Further, the agents increased serum, cardiac
      and renal total antioxidant capacity. Interestingly, the combination of agents
      had further effects on all the parameters compared to treatment with each single 
      agent. CONCLUSIONS: The study suggests that the additive protective effects of
      vit D and COQ10 when used alone or concurrent with vals treatment in hypertensive
      rats may be due to their effects as antioxidants, anticytokines and blood
      pressure conservers.
CI  - Copyright (c) 2017 Southern Society for Clinical Investigation. Published by
      Elsevier Inc. All rights reserved.
FAU - Shamardl, Hanan A
AU  - Shamardl HA
AD  - Department of Pharmacology (HAS), Faculty of Medicine, Fayoum University, Fayoum,
      Egypt; Department of Pharmacology & Clinical Pharmacy (SME), Faculty of Pharmacy,
      Umm Al-Qura University, Makkah, Saudi Arabia. Electronic address:
      [email protected]
FAU - El-Ashmony, Sahar M
AU  - El-Ashmony SM
AD  - Department of Clinical Pharmacology, Faculty of Medicine, Cairo University,
      Cairo, Egypt; Department of Pharmacology & Clinical Pharmacy (SME), Faculty of
      Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
FAU - Kamel, Hala F
AU  - Kamel HF
AD  - Department of Biochemistry (HFK, SHF), Faculty of Medicine, Umm Al-Qura
      University, Makkah, Saudi Arabia; Department of Medical Biochemistry, Faculty of 
      Medicine, Ain Shams University, Cairo, Egypt.
FAU - Fatani, Sameer H
AU  - Fatani SH
AD  - Department of Biochemistry (HFK, SHF), Faculty of Medicine, Umm Al-Qura
      University, Makkah, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20170410
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Vitamins)
RN  - 1339-63-5 (Ubiquinone)
RN  - 1406-16-2 (Vitamin D)
RN  - 80M03YXJ7I (Valsartan)
RN  - EJ27X76M46 (coenzyme Q10)
RN  - V55S2QJN2X (NG-Nitroarginine Methyl Ester)
SB  - AIM
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/pharmacology
MH  - Animals
MH  - Cardiovascular Diseases/drug therapy
MH  - Hypertension/chemically induced/*drug therapy
MH  - Kidney Diseases/drug therapy
MH  - NG-Nitroarginine Methyl Ester/toxicity
MH  - Rats
MH  - Rats, Wistar
MH  - Ubiquinone/*analogs & derivatives/pharmacology/therapeutic use
MH  - Valsartan/*pharmacology
MH  - Vitamin D/*pharmacology/therapeutic use
MH  - Vitamins/pharmacology
OTO - NOTNLM
OT  - Antioxidants
OT  - Coenzyme Q10
OT  - Vitamin D
OT  - l-Arginine analog hypertensive rats
EDAT- 2017/09/03 06:00
MHDA- 2017/09/09 06:00
CRDT- 2017/09/03 06:00
PHST- 2016/12/18 [received]
PHST- 2017/03/25 [revised]
PHST- 2017/04/07 [accepted]
AID - S0002-9629(17)30213-6 [pii]
AID - 10.1016/j.amjms.2017.04.007 [doi]
PST - ppublish
SO  - Am J Med Sci. 2017 Aug;354(2):190-198. doi: 10.1016/j.amjms.2017.04.007. Epub
      2017 Apr 10.